The original International Prognostic Index (IPI) was based upon multivariate analysis of survival of 2031 patients with aggressive non-Hodgkin-lymphomas treated between 1982 and 1987. Several histological subtypes were included, and patients were treated with various doxorubicin-containing chemotherapy combinations. Although the NCCN-IPI and R-IPI have been developed for diffuse large B cell lymphoma (DLBCL) in the rituximab era, the original IPI appears to retain some prognostic significance. The original IPI is also of prognostic significance in other aggressive lymphomas, including peripheral T cell lymphoma not otherwise specified (PTCL-NOS) and Burkitt lymphoma.
|Low risk: 5-year survival of 73%||0–1 points|
|Low–Intermediate risk: 5-year survival of 51%||2 points|
|Intermediate-High risk: 5-year survival of 43%||3 points|
|High risk: 5-year survival of 26%||4–5 points|
|Points per true condition|
|Age > 60 years||1|
|Performance status ≥ 2||1|
|LDH > reference range||1|
|Ann Arbor stage ≥ 3||1|
|≥ 2 extranodal sites of disease||1|
- A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. New Engl J Med 1993; 329: 987-994.
- Ziepert M et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 2373-2380.
- Weisenburger DD et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011; 117:3402-3408.
- Mead GM et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002; 13: 1264-1274.